FDA may approve COVID-19 drug for 16- and 17-year-olds as soon as next week

The Food and Drug Administration may authorize a COVID-19 booster from Pfizer Inc.
PFE,
-2.96%

and BioNTech SE
BNTX,
+ 4.17%

for use by 16- and 17-year-olds as soon as next week when there is concern about a new, possibly more contagious variant, according to a person familiar with the plan.

The agency is planning to act quickly on requests from companies to license boosters to 16- and 17-year-olds, according to a person familiar with the matter. So far, only people 18 years or older is eligible for boosters.